Abbott Laboratories Aktie
116,80 EUR +0,14 EUR +0,12 %
XETRA
126,31 USD -0,46 USD -0,36 %
BTT
Werbung
Abbott Laboratories Rating
Abbott Laboratories Aktie Moody's Rating
Aa3
C
A3
Aaa
Investmentwürdig - Hohe Sicherheit
Investmentwürdig - Mittlere Sicherheit
Nicht als Investment geeignet
Investmentwürdig - Mittlere Sicherheit
Nicht als Investment geeignet
| Rating | Aa3 | Rating Typ Bank Financial Strength Rating Insurance Financial Strength Rating Enhanced Rating Insured Rating Long-Term Bank Deposit Rating Long-Term OSO Rating Long-Term Debt Rating Money Market Fund Rating Modeled Shadow Rating Management Quality Rating Probability of Default Rating Pfd/Pref Stock Rating Prospective Pfd/Pref Rating Short-Term Bank Deposit Rating Speculative Grade Liquidity Rating Prospective LT Debt Rating Short-Term Insurance Financial Strength Rating Short-Term OSO Rating Servicer Quality Short-Term Debt Rating Lloyd´s Syndicate Performance Rating Underlying Rating Unknown - for conversion use only | Long-Term Debt Rating |
| Letzte Aktion | Upgrade | Moody's Büro in | - |
Anleihen von Abbott Laboratories mit Moody's Ratings
| Emittent | Anzahl Anleihen | Ratings |
|---|---|---|
| Abbott Laboratories | 7 | Aa3 |
Werbung
Werbung
Moody's Ratings Peer Group
| Aktie | Rating |
|---|---|
| AstraZeneca PLC | A1 |
| Bayer | Baa3 |
| Celgene Corp. | A3 |
| Fresenius SE & Co. KGaA (St.) | Ba1 |
| Fresenius SE & Co. KGaA (St.) | Baa3 |
| Johnson & Johnson | Aaa |
| Merck Co. | A1 |
| Merck KGaA | A3 |
| Merck KGaA | Baa1 |
| Pfizer Inc. | A1 |
| Pfizer Inc. | A2 |
| Sanofi S.A. | A1 |